Chlorhexidine Partners Network to Offer Webinar on Chlorhexidine in Vascular
Experts Will Discuss Antiseptic’s Role in Preventing Bloodstream Infections
READING, Pa. -- November 12, 2012
The Chlorhexidine Partners Network (CPN), a new organization composed of
leading makers of patient safety technology, is sponsoring a free webinar on
the importance of chlorhexidine use to protect patient safety during vascular
access. The network also recently launched its new website, at
The webinar, titled “The Role of Chlorhexidine in Vascular Access: Protecting
Your Patient,” will be presented on Wednesday, Nov. 14. Two sessions will be
offered, at 12:00 p.m. EST and 3:00 p.m. EST.
The webinar will be moderated by Paul L. Blackburn, RN, BSN, MNA, VA-BC,
president of the Association for Vascular Access (AVA) and Senior Marketing
Director, Clinical Education for RyMed Technologies, Inc. (Franklin, Tenn.)
“At AVA, one of our main objectives is the prevention of central
line-associated bloodstream infections (CLABSIs),” said Blackburn. “As
everyone from the CDC to major medical societies now recognizes,
chlorhexidine-based products are a proven means of minimizing CLABSI risk.
Anyone involved in vascular access should consider attending this webinar to
learn more about how chlorhexidine protects patients with an IV line.”
Webinar presenters will be Keith Kaye, M.D., MPH and Constance Girgenti, RN,
VA-BC. Dr. Kaye is a Professor of Medicine in the Division of Infectious
Diseases and Department of Medicine at Wayne State University and Detroit
Medical Center. Ms. Girgenti is Vascular Access Coordinator at Provena St.
Joseph Medical Center, in Joliet, Ill. She also serves as a vascular access
specialist consultant for the 11-hospital Presence Health System in Illinois.
The webinar is a project of three CPN members involved in vascular access,
ARROW International (Reading, PA), PDI, Inc and RyMed Technologies, Inc.
Chlorhexidine is a widely used antiseptic for numerous applications in
medicine, dentistry, and household use and is the gold standard for several of
those applications. It is effective against both Gram-positive and
Gram‐negative bacteria and fungi.^11 All of these organisms are commonly
implicated in hospital-associated infections (HAIs) such as CLABSIs. Because
of its low toxicity level, chlorhexidine offers a safe side-effect
Chlorhexidine inactivates microorganisms with a broader spectrum than other
antimicrobials (e.g. antibiotics) and has a quicker kill rate than other
antimicrobials (e.g. povidone iodine).^1 When applied in vitro, it has been
shown to kill nearly 100% of Gram-positive and Gram-negative bacteria within
In its Guidelines for the Prevention of Intravascular Catheter-Related
Infections (2011), the Centers for Disease Control and Prevention (CDC)
recommends numerous products containing chlorhexidine as evidence-based
interventions that may prevent central line-associated bloodstream infections
(CLABSIs).^20 Vascular access products that often include chlorhexidine
include central venous catheters, peripherally inserted central venous
catheters (PICCs), vascular access site dressings, skin preparation solutions,
and needleless IV connectors.
Experts consider hand hygiene to be the single most effective measure for
preventing bloodstream infections. Chlorhexidine solutions are often used for
hand hygiene in hospital settings because hand washing with chlorhexidine
solutions has been shown to reduce skin flora by 86% to 92%. As a surgical
scrub, chlorhexidine has been shown to reduce skin flora while also
maintaining its antimicrobial activity for up to six hours.^13
Chlorhexidine is recommended as part of various standards of care by such
notable professional societies and government agencies as the CDC, the World
Health Organization, the Society for Healthcare Epidemiology of America,
(SHEA), the American Society of Anesthesiologists, the Institute for
Healthcare Improvement, the Infusion Nurses Society (INS), and the Oncology
For example, the CDC, INS, and SHEA all recommend chlorhexidine-based
solutions for skin preparation prior to vascular access.
For more information about the webinar and to register, visit
www.chlorhexidinefacts.com, click here for the 12:00 p.m. EST webinar or click
here for the 3:00 p.m. EST webinar.
* Member product: ARROW® CVC with ARROWg+ard® Technology
* Member product: ARROW PICC with Chlorag+ard® Technology
* Member product: InVision-Plus® CS™ with Chlorhexidine+Silver Ion Engineering
*Member product: Chlorascrub™ Swab & Swabsticks
About the Chlorhexidine Partners Network
The Chlorhexidine Partners Network was created by manufacturers of patient
safety technology to support chlorhexidine as an infection prevention
molecule. Each organization offers chlorhexidine solutions designed to protect
patients from infection. The goal of the partnership is to educate the
infection control community and other clinicians about the chlorhexidine
molecule, demonstrate the evidence for different chlorhexidine applications,
contrast chlorhexidine with other antimicrobials, promote antimicrobial
stewardship, and share information about sponsored chlorhexidine products.
For more information on the network and chlorhexidine, access
www.chlorhexidinefacts.com or call 610-378-0131. The network is headquartered
in Reading, PA.
References available at http://www.chlorhexidinefacts.com/references.html
ARROW, ARROWg+ard, Chlorag+ard and Teleflex are trademarks or registered
trademarks of Teleflex Incorporated or its affiliates.
InVision-Plus, InVision-Plus CS and RyMed are trademarks or registered
trademarks of RyMed Technologies, Incorporated.
Chlorascrub and PDI are trademarks or registered trademarks of Nice-Pak
© 2012 Teleflex Incorporated. All rights reserved. 2012-1510
Dowling & Dennis Public Relations
Liz Dowling, 415-388-2794
Press spacebar to pause and continue. Press esc to stop.